99mTc-labeled iron oxide nanoparticles for dual-contrast (T1/T2) magnetic resonance and dual-modality imaging of tumor angiogenesis

Journal of Biomedical Nanotechnology

Volumn 11, Issue 6, 2015, Pages 1027-1037

  Xue, Sihan ^a   Zhang, Chunfu ^a   Yang, Yi ^a   Zhang, Lu ^a   Cheng, Dengfeng ^b   Zhang, Jianping ^c   Shi, Hongcheng ^b   Zhang, Yingjian ^c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Angiogenesis; Dual MRI contrast; Iron oxide nanoparticles; Molecular imaging; SPECT MRI

Indexed keywords

IRON; IRON OXIDES; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; NANOMAGNETICS; PARTICLE BEAMS; PEPTIDES; PHOTONS; PROBES; RESONANCE; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYNTHESIS (CHEMICAL); TOMOGRAPHY; TUMORS;

ANGIOGENESIS; DUAL-MODAL IMAGING; DUAL-MODALITY IMAGING; IRON OXIDE NANOPARTICLE; MRI CONTRASTS; SPECT/MRI; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; TUMOR ANGIOGENESIS;

MOLECULAR IMAGING;

BETA3 INTEGRIN; RADIOPHARMACEUTICAL AGENT; ULTRA SMALL SUPER PARAMAGNETIC IRON OXIDE NANOPARTICLE ARGINYLGLYCYLASPARTIC ACID TC 99M; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE; MOLECULAR PROBE; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CT SPECT SCANNER; CYTOTOXICITY; DRUG CONJUGATION; DRUG SPECIFICITY; FEMALE; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LUNG TUMOR; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTICLE SIZE; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; WHOLE BODY MRI; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; EVALUATION STUDY; HUMAN; METABOLISM; MOLECULAR PROBE; MULTIMODAL IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PHARMACOKINETICS; PROCEDURES; SCINTISCANNING; VASCULARIZATION;

ANIMALS; CELLS, CULTURED; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; MOLECULAR PROBES; MULTIMODAL IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84918514198     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2023     Document Type: Article

References (53)

1. A. H. Schmieder, P. M. Winter, T. A. Williams, J. S. Allen, G. Hu, H. Zhang, S. D. Caruthers, S. A. Wickline, and G. M. Lanza, Molecular MR imaging of neovascular progression in the Vx2 tumor with avb3- targeted paramagnetic nanoparticles. Radiology 268, 470 (2013).
2. F. Danhier, A. L. Breton, and V. Preìat, RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharmaceutics 9, 2961 (2012).
3. J. Lee, T. S. Lee, J. Ryu, S. Hong, M. Kang, K. Im, J. H. Kang, S. M. Lim, S. Park, and R. Song, RGD peptide-conjugated multimodal NaGdF4:Yb31/Er31 nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J. Nucl. Med. 54, 96 (2013).
4. P. Liu, J. Li, C. Zhang, and L. X. Xu, Micro-CT molecular imaging of tumor angiogenesis using a magnetite nano-cluster probe. J. Biomed. Nanotechnol. 96, 1041 (2013).
5. M. Tan and Z.-R. Lu, Integrin targeted MR imaging. Theranostics 1, 83 (2011).
6. Y. Lui, Y. Yang, and C. Zhang, A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αvβ3 with magnetic probes. Int. J. Nanomed. 8, 1083 (2013).
7. C. Khemtong, C. W. Kessinger, J. Ren, E. A. Bey, S. G. Yang, J. S. Guthi, D. A. Boothman, A. D. Sherry, and J. Gao, In vivo offresonance saturation magnetic resonance imaging of αvβ3-targeted superparamagnetic nanoparticles. Cancer Res. 69, 1651 (2009).
8. C. Zhang, X. Xie, S. Liang, M. Li, Y. Liu, and H. Gu, Monodispersed high MR sensitive magnetite nano cluster probe for detection of nascent tumor by MR molecular imaging. Nanomedicine: NBM 8, 996 (2012).
9. A. Ahsan, A. Aziz, M. A. Arshad, O. Ali, M. Nauman, N. M. Ahmad, and A. Elaissari, Smart magnetically engineering colloids and biothin films for diagnostics applications. J. Colloid Sci. Biotechnol. 2, 19 (2013).
10. P. Caravan, Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 35, 512 (2006).
11. E. Terreno, D. D. Castelli, A. Viale, and S. Aime, Challenges for molecular magnetic resonance imaging. Chem. Rev. 110, 3019 (2010).
12. J. R. McCarthy and R. Weissleder, Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60, 1241 (2008).
13. C. Tassa, S. Y. Shaw, and R. Weissleder, Dextran-coated iron oxide nanoparticles: A versatile platform for targeted molecular imaging, molecular diagnostics and therapy. Acc. Chem. Res. 44, 842 (2011).
14. J. E. Rosena, L. Chana, D.-B. Shieh, and F. X. Gu, Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine: NBM 8, 275 (2012).
15. S. Ravina and N. H. Singh, Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs. J. Biomed. Nanotechnol. 7, 489 (2013).
16. J. W. M. Bulte and D. L. Kraitchman, Iron oxide MR contrast agents for molecular and cellular imaging. NMR in Biomedicine 17, 484 (2004).
17. M. A. Brown and R. C. Semelka, MRI: Basic Principles and Applications, Wiley-Liss, New York (2003).
18. P. Caravan, J. J. Ellison, T. J. McMurry, and R. B. Lauffer, Gadolinium( III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem. Rev. 99, 2293 (1999).
19. A. Datta and K. N. Raymond, Gd-Hydroxypyridinone (HOPO)- based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc. Chem. Res. 42, 938 (2009).
20. F. Hu and Y. S. Zhao, Inorganic nanoparticle-based T1 and T1/T2 magnetic resonance contrast probes. Nanoscale 4, 6235 (2012).
21. A. J. L. Villaraza, A. Bumb, and M. W. Brechbiel, Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: The interplay between size, function, and pharmacokinetics. Chem. Rev. 110, 2921 (2010).
22. M. Botta and L. Tei, Relaxivity enhancement in macromolecular and nanosized GdIII-based MRI contrast agents. Eur. J. Inorg. Chem. 2012, 1945 (2012).
23. D. A. Sipkins, D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski, and K. C. P. Li, Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med. 4, 623 (1998).
24. P. M. Winter, S. D. Caruthers, A. Kassner, T. D. Harris, L. K. Chinen, J. S. Allen, E. K. Lacy, H. Zhang, J. D. Robertson, S. A. Wickline, and G. M. Lanza, Molecular imaging of angiogenesis in nascent Vx- 2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838 (2003).
25. J. G. Penfield and R. F. Reilly, What nephrologists need to know about gadolinium. Nat. Clin. Pract. Nephrol. 3, 654 (2007).
26. L. H. Reddy, J. L. Arias, J. Nicolas, and P. Couvreur, Magnetic nanoparticles: Design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112, 5818 (2012).
27. S. L. Byrne, D. Krishnamurthy, and M. Wessling-Resnick, Pharmacology of iron transport. Annu. Rev. Pharmacol. Toxicol. 53, 2.1 (2013).
28. J. Schnorr, S. Wagner, C. Abramjuk, I. Wojner, T. Schink, T. J. Kroencke, E. Schellenberger, B. Hamm, H. Pilgrimm, and M. Taupitz, Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest. Radiol. 39, 546 (2004).
29. T. Matthias, W. Susanne, S. Jörg, K. Irina, P. Herbert, B.-F. Henrike, and H. Bernd, Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest. Radiol. 39, 394 (2004).
30. B. H. Kim, N. Lee, H. Kim, K. An, Y. I. Park, Y. Choi, K. Shin, Y. Lee, S. G. Kwon, H. B. Na, J.-G. Park, T.-Y. Ahn, Y.-W. Kim, W. K. Moon, S. H. Choi, and T. Hyeon, Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for highresolution T1 magnetic resonance imaging contrast agents. J. Am. Chem. Soc. 133, 12624 (2011).
31. T. Borase, T. Ninjbadgar, A. Kapetanakis, S. Roche, R. O'Connor, C. Kerskens, A. Heise, and D. F. Brougham, Stable aqueous dispersions of glycopeptide-grafted selectably functionalized magnetic nanoparticles. Angew. Chem. Int. Ed. 52, 3164 (2013).
32. W. Xiao, J. Lin, M. Li, Y. Ma, Y. Chen, C. Zhang, D. Li, and H. Gu, Prolonged in vivo circulation time by zwitterionic modification of magnetite nanoparticles for blood pool contrast agents. Contrast Media Mol. Imaging 7, 320 (2012).
33. H. Ding and F. Wu, Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics 2, 1040 (2012).
34. Y. Zhang, Y. Yang, and W. Cai, Multimodality imaging of integrin αvβ3 expression. Theranostics 1, 135 (2011).
35. L.-H. Shen, J.-F. Bao, D. Wang, Y.-X. Wang, Z.-W. Chen, L. Ren, X. Zhou, X.-B. Ke, M. Chen, and A.-Q.Yang, One-step synthesis of monodisperse, water-soluble ultra-small Fe3O4 nanoparticles for potential bioapplication. Nanoscale 5, 2133 (2013).
36. C. R. Ram Prakash, M. Rashi, S. Gurjaspreet, K. Ankur, B. Narmada, S. Sweta, K. Hemanth, P. Manoj, and K. M. Anil, Evaluation of folate conjugated superparamagnetic iron oxide nanoparticles for scintigraphic/magnetic resonance imaging. J. Biomed. Nanotechnol. 9, 323 (2013).
37. C. Alric, I. Miladi, D. Kryza, J. Taleb, F. Lux, R. Bazzi, C. Billotey, M. Janier, P. Perriat, S. Roux, and O. Tillementa, The biodistribution of gold nanoparticles designed for renal clearance. Nanoscale 5, 5930 (2013).
38. M. Irigoyen, M. J. Pajares, J. Agorreta, M. P. Ponz-Sarvisé, E. Salvo, M. D. Lozano, R. Pío, I. Gil-Bazo, and A. Rouzaut, RTeGseaFrcBh I expression is associated with a better response to chemotherapy in NSCLC. Mol. Cancer 9, 130 (2010).
39. Q. Li, G. Tang, S. Xue, X. He, P. Miao, Y. Li, J. Wang, L. Xiong, Y. Wang, C. Zhang, and G.-Y. Yang, Silica-coated superparamagnetic iron oxide nanoparticles targeting of EPCs in ischemic brain injury. Biomaterials 34, 4982 (2013).
40. M. Oostendorp, K. Douma, T. M. Hackeng, A. Dirksen, M. J. Post, M. A. M. J. Zandvoort, and W. H. Backes, Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-Labeled paramagnetic quantum dots. Cancer Res. 68, 7676 (2008).
41. D. Psimadas, G. Baldi, C. Ravagli, P. Bouziotis, S. Xanthopoulos, M. C. Franchini, P. Georgoulias, and G. Loudos, Preliminary evaluation of a 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core: In vivo biodistribution. J. Biomed. Nanotechnol. 8, 575 (2012).
42. J. Wan, W. Cai, X. Meng, and E. Liu, Monodisperse watersoluble magnetite nanoparticles prepared by polyol process for high-performance magnetic resonance imaging. Chem. Commun. 2007, 5004 (2007).
43. Y. M. Huh, Y. W. Jun, H. T. Song, S. Kim, J. S. Choi, J. H. Lee, S. Yoon, K. S. Kim, J. S. Shin, J. S. Suh, and J. Cheon, In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc. 127, 12387 (2005).
44. F. Xu, D. Lei, X. Du, C. Zhang, X. Xie, and D. Yin, Modification of MR molecular imaging probes with cysteine-terminated peptides and their potential for in vivo tumour detection. Contrast Media Mol. Imaging 6, 46 (2011).
45. S.-B. Yu and A. D. Watson, Metal-based x-ray contrast media. Chem. Rev. 99, 2353 (1999).
46. U. I. Tromsdorf, O. T. Bruns, S. C. Salmen, U. Beisiegel, and H. Weller, Highly effective, nontoxic T1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles. Nano Lett. 9, 4434 (2009).
47. F. Hu, Q. Jia, Y. Li, and M. Gao, Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2- weighted magnetic resonance imaging. Nanotechnology 22, 245604 (2011).
48. A. Roch, R. N. Muller, and P. Gillis, Theory of proton relaxation induced by superparamagnetic particles. J. Chem. Phys. 110, 5403 (1999).
49. Y.-W. Jun, J.-H. Lee, and J. Cheon, Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew. Chem. Int. Ed. 47, 5122 (2008).
50. C. Zhang, M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf, M. Bock, M. Eisenhut, W. Semmler, and F. Kiessling, Specific targeting of tumor angiogenesis by RGDconjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67, 1555 (2007).
51. T. Jiang, C. Zhang, X. Zheng, X. Xu, X. Xie, H. Liu, and S. Liu, Noninvasively characterizing the different αvβ3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. Int. J. Nanomed. 4, 241 (2009).
52. J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27 (1995).
53. P. Carmeliet and R. K. Jain, Angiogenesis in cancer and other diseases. Nature 407, 249 (2000).